This site is intended for U.S. healthcare professionals.

Visit Pfizer MedicalVisit Pfizer MedicalLoading

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

About HYMPAVZIAbout
HYMPAVZIOverviewHYMPAVZI in ActionEfficacyEfficacyStudy DesignPrimary EndpointsSecondary EndpointsSafetyDosing & AdminDosing 

& AdminDosingPen OverviewInjection OverviewPatient ProfilesPatient
ProfilesIdentifying PatientsUnmet NeedsResourcesResourcesResourcesPatient Savings & Support
Full Prescribing InformationPatient InformationInstructions for UseIndication Patient Site

For routine prophylaxis in patients 12 years and older with hemophilia A or B without inhibitors1

Once-weekly HYMPAVZI is the first and only subcutaneous prophylactic treatment that comes in a fixed-dose,* prefilled pen.1-3

  • Innovative mechanism of action: anti-TFPI1-4†
  • Bleed protection delivered1‡
  • Prefilled pen. Fixed dose.* 
Once weekly1 
 Identify eligible patients Loading
It starts
with a click.
One click starts their treatment. The next one means they're ready to go. Meet the HYMPAVZI pen Loading

For routine prophylaxis in patients 12 years and older with hemophilia A or B without inhibitors1

Once-weekly HYMPAVZI is the first and only subcutaneous prophylactic treatment that comes in a fixed-dose,* prefilled pen.1-3

  • Innovative mechanism of action: anti-TFPI1-4† 
  • Bleed protection delivered1‡
  • Prefilled pen. Fixed dose.* Once weekly1 
 Identify eligible patients Loading Innovative mechanism of action: anti-TFPI

HYMPAVZI is a human monoclonal antibody that inhibits TFPI and helps to achieve hemostasis through rebalancing1-4

 See how HYMPAVZI works Loading Bleed protection delivered

In the BASIS study, HYMPAVZI was demonstrated to protect patients from bleeds1‡

 See efficacy data Loading Designed for ease of use

Once-weekly HYMPAVZI comes in a prefilled pen for subcutaneous injection1

 Learn how to use HYMPAVZI  Loading Safety profile

HYMPAVZI demonstrated safety in the phase 3 BASIS study1

 See safety data LoadingABR=annualized bleed rate; TFPI=tissue factor pathway inhibitor.The recommended dosage of HYMPAVZI on day 1 is a loading dose of 300 mg (two 150 mg pens) by subcutaneous injection. On day 8 and thereafter, the weekly maintenance dose is 150 mg (one pen) by subcutaneous injection. A dose adjustment to 300 mg subcutaneous injection weekly can be considered in patients weighing ≥50 kg when control of bleeding events is judged to be inadequate by the healthcare provider. Safety and efficacy of HYMPAVZI at doses above 300 mg weekly have not been established.1HYMPAVZI is a TFPI antagonist.192% reduction in treated bleeds on HYMPAVZI compared to on-demand factor-based treatment (3.18 ABR vs 38.00 ABR). 35% reduction in treated bleeds on HYMPAVZI compared to routine factor-based prophylaxis treatment (5.08 ABR vs 7.85 ABR).1
Stay up to date on HYMPAVZI

Be the first to know about product updates, events, and more. 

 Sign up Loading Sign up Loading HYMPAVZI is the latest hemophilia 
therapy from Pfizer—representing our 
commitment of over 25 years to the 
hemophilia community.1,5 References:1. HYMPAVZI. Prescribing Information. Pfizer Inc.; 2024. 2. Butterfield JSS, et al. Mol Ther. 2020;28(3):997-1015. 3. Srivastava A, et al. Haemophilia. 2020;26(suppl 6):1-158. 4. Pittman DD, et al. Res Pract Thromb Haemost. 2022;6(2):e12679. 5. Center for Biologics Evaluation and Research, US Food and Drug Administration, US Department of Health and Human Services. CBER Approval Letter, Coagulation Factor IX (Recombinant), Genetics Institute, Inc. February 11, 1997. Accessed April 26, 2024. wayback.archive- it.org/7993/20170723024338/https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm057039.htmHYMPAVZI is a trademark of Pfizer Inc.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-HYM-USA-0073
Indications and usageHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
 
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.
Helix ISI Modal Headline Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Important Safety InformationHYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist and may increase the risk of thromboembolic complications. Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated. If factor VIII or factor IX products are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose of factor VIII or factor IX according to the product label is recommended.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to, urticaria and pruritus). If HYMPAVZI-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue HYMPAVZI and seek immediate emergency treatment.

Based on its mechanism of action, HYMPAVZI may cause fetal harm when administered to a pregnant woman. Verify that females of reproductive potential are not pregnant prior to initiating HYMPAVZI. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

A serious adverse reaction of peripheral swelling occurred in one patient. Adverse reactions reported in ≥3% of patients treated with HYMPAVZI in clinical trials included injection site reaction (9% of patients); headache (7% of patients); pruritus (3% of patients).IndicationHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.